NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Longitudinal Assessment of Transient Elastography in Cystic Fibrosis

Completed

Conditions: Cystic Fibrosis Liver Disease

First Posted Date: 2016-12-23

Last Posted Date: 2025-04-11

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 141

Registration Number: NCT03001388

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Ann & Robert H. Lurie Children's, Chicago, Illinois, United States

and more 5 locations

Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation

Recruiting

Conditions: Tissue Donors
Hematopoietic Stem Cell Transplantation

First Posted Date: 2016-12-22

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2000

Registration Number: NCT03000244

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study

Phase 3

Suspended

Conditions: Stage IV Colorectal Cancer AJCC v7
Metastatic Colorectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Fluorouracil
Drug: Leucovorin
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2016-12-20

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT02997228

Locations: 🇺🇸
Broadlawns Medical Center, Des Moines, Iowa, United States
🇺🇸
Mercy Medical Center - Des Moines, Des Moines, Iowa, United States
🇺🇸
MaineHealth Waldo Hospital, Belfast, Maine, United States

and more 443 locations

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Phase 1

Active, not recruiting

Conditions: Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Brain
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Drug: Ropidoxuridine
Radiation: Whole-Brain Radiotherapy

First Posted Date: 2016-12-15

Last Posted Date: 2025-03-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT02993146

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 11 locations

Hyperthyroid Follow-Up Study

Completed

Conditions: All-Cause Mortality
Thyroid and Other Cancer Mortality
Circulatory and Other Disease Mortality

First Posted Date: 2016-12-12

Last Posted Date: 2020-10-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35593

Registration Number: NCT02989103

Locations: 🇺🇸
Social and Scientific Systems, Inc., Durham, North Carolina, United States

MRI to Characterize and Predict CF Liver Disease in PUSH Cohort

Completed

Conditions: Pancreatic Insufficiency
Cystic Fibrosis Liver Disease

First Posted Date: 2016-12-01

Last Posted Date: 2025-04-11

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 115

Registration Number: NCT02979340

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

and more 5 locations

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Phase 2

Active, not recruiting

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative
Anaplastic Large Cell Lymphoma, ALK-Positive
Apocrine Carcinoma
Carcinoma Arising From Cylindroma
Carcinoma Arising From Spiradenoma
Digital Papillary Adenocarcinoma
Endocrine Mucin-Producing Sweat Gland Carcinoma
Extramammary Paget Disease
Extraocular Sebaceous Carcinoma
Hidradenocarcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Procedure: Positron Emission Mammography
Biological: Talimogene Laherparepvec

First Posted Date: 2016-12-01

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT02978625

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States

and more 33 locations

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Phase 2

Active, not recruiting

Conditions: Recurrent Glioblastoma

Interventions: Biological: Bevacizumab
Drug: Cediranib
Drug: Cediranib Maleate
Drug: Olaparib

First Posted Date: 2016-11-28

Last Posted Date: 2025-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT02974621

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 24 locations

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Neoplasm in the Brain
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Osimertinib
Biological: Bevacizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging

First Posted Date: 2016-11-23

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 112

Registration Number: NCT02971501

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 15 locations

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Phase 2

Active, not recruiting

Conditions: Hepatocellular Carcinoma
Cirrhosis

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Questionnaire Administration
Other: Placebo Administration
Drug: Simvastatin

First Posted Date: 2016-11-21

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT02968810

Locations: 🇵🇷
Centro Comprensivo de Cancer de UPR, San Juan, Puerto Rico
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy